The case for using 5-aminosalicyclates in Crohn's disease: pro.
Mesalamine has a well-established role in the management of ulcerative colitis. However, its role in the management of Crohn's disease (CD) is less clear. Studies evaluating its therapeutic value in CD have produced both positive and negative results. Meta-analyses have not clarified the situation, possibly because they have combined studies of different design. This debate critically examines the evidence for and against the use of mesalamine in CD.
Hanauer
Stephen B
SB
Department of Medicine and Clinical Pharmacology, University of Chicago, Chicago, Illinois, USA.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D006801:Humans; D019804:Mesalamine / Q000627:therapeutic use*; D015201:Meta-Analysis as Topic; D012460:Sulfasalazine / Q000627:therapeutic use; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D012460:Sulfasalazine; D019804:Mesalamine